BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Spago Nanomedical Year-End Report January-December, 2021

  The regulatory preclinical program with Tumorad® (177Lu-SN201) were completed and show a good safety margin for clinically relevant doses.

  February 2, 2022

   · 

  5 min read
• Drug Development

  NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease

  NorthSea Therapeutics B.V., a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, announces it has initiated a Phase 1 study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD.

  February 2, 2022

   · 

  6 min read
• Genetown

  Avidien Technologies Receives $4M Investment from BroadOak Capital Partners

  Avidien announced a new financing round of $4M from BroadOak Capital Partners.

  February 2, 2022

   · 

  2 min read
• Medtronic announces first procedure in Europe with Hugo™ robotic-assisted surgery system

  Medtronic plc, a global leader in healthcare technology, and OLV Hospital Aalst announced that the first clinical procedure in Europe was performed with the Hugo™ robotic-assisted surgery system.

  February 2, 2022

   · 

  6 min read
• Business

  AmerisourceBergen Reports Fiscal 2022 First Quarter Results

  AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022 first quarter ended December 31, 2021.

  February 2, 2022

   · 

  37 min read
• Business

  IDEXX Laboratories Announces Fourth Quarter and Full Year 2021 Results

  Achieves 11% fourth quarter revenue growth as reported and 10.5% organic, driven by 13% CAG Diagnostics recurring revenue growth (reported and organic).

  February 2, 2022

   · 

  38 min read
• Pharm Country

  Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

  Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.

  February 2, 2022

   · 

  1 min read
• Drug Development

  Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study’s Data Safety Monitoring Board (DSMB).

  February 2, 2022

   · 

  8 min read
• Oncology Companion Diagnostic Market Size, Scope, Segmentation and Key Players

  Companion diagnostics are developed along with drugs so as to assist in the exclusion or selection of groups for the purpose of treating patients with a certain drug, based on biological characteristics of the selected pool of patients.

  February 2, 2022

   · 

  6 min read
• Gastroesophageal Reflux Disease (GERD) Devices Market Key Drivers and New Developments

  The drive for clinical procedures and devices in the management of gastroesophageal reflux disease stemmed from the wide prevalence of the condition.

  February 2, 2022

   · 

  6 min read